Increase diversity to improve clinical translation and strengthen pain management outcomes.
The goal of preclinical drug development is to identify potential therapeutic compounds and gain an understanding of disease pathways or target...
Development of a new symptomatic neuroma model
Neuroma in humans is a challenging condition that often leads to persistent pain in residual limbs. Despite its prevalence, this condition proves to...
New Publication - A novel sensory wave (p25) in MOG-EAE model
MD Biosciences has published a new article in the Journal of Pain describing a novel sensory wave (P25) in the MOG-induced EAE model. This article...
Three ways to approach translation
As the general population continues to age, the economic burden of chronic pain and neurodegenerative diseases is increasing and becoming...
The effect of the housing environment and handling on behavior assays
An excerpt from MD Biosciences publication in the Autumn 2022 issue of Göttingen Minipigs Magazine. MD Biosciences operates a neuroscience research...
electrophysiology: an in vivo biomarker for neurology models
Animal models are commonly used in preclinical development to mimic human disease and response. Over the past several decades, drug developers have...
Preclinical Human Pain Models. Translating to Clinic
Management of acute pain related to surgical intervention, termed postoperative pain, continues to be a major problem facing physicians and patients...
A minipig Model of Incisional pain
The use of animal models for the research of post-operative pain (POP) has been well described[1]. Most POP studies that have been performed to date...
Do clinical scores tell us all we need to know?
Multiple sclerosis is a disease in which the immune system attacks the myelin sheath that covers nerve fibers. People suffering from this autoimmune...